AbbVie (ABBV) Long-Term Investments (2012 - 2026)

AbbVie (ABBV) has 15 years of Long-Term Investments data on file, last reported at $268.0 million in Q1 2026.

• Quarterly Long-Term Investments fell 6.62% year-over-year to $268.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268.0 million (down 6.62% YoY) and the FY2025 annual result came in at $268.0 million, down 3.94% from the prior year.
• Long-Term Investments held at $268.0 million in Q1 2026 per ABBV's latest filing, from $268.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $310.0 million in Q2 2025 and bottomed at $235.0 million in Q3 2022.
• The 5-year median for Long-Term Investments is $272.0 million (2024), against an average of $273.6 million.
• The widest annual swing landed in 2022, when Long-Term Investments declined 14.75%; it then advanced 26.14% in 2023.
• Tracing ABBV's Long-Term Investments over 5 years: stood at $241.0 million in 2022, then gained by 26.14% to $304.0 million in 2023, then fell by 8.22% to $279.0 million in 2024, then decreased by 3.94% to $268.0 million in 2025, then changed by 0.0% to $268.0 million in 2026.
• Per Business Quant, the three latest ABBV Long-Term Investments figures stand at $268.0 million (Q1 2026), $268.0 million (Q4 2025), and $291.0 million (Q3 2025).

Peer Comparison